Results of searching in PCT for:
(melatonin AND zolpidem): 251 records
Showing records 1 to 25 of 251 :

[Search Summary]

Next 25 records

Start At 200

Refine Search

(melatonin AND zolpidem)

RSS

	Title	Pub. Date	Int. Class	App. Num
1.	(WO 2009/042440) 1-METHYL NICOTINAMIDE AND DERIVATIVES FOR TREATMENT OF GASTRIC INJURY	02.04.2009	A01N 43/40	PCT/ US2008/076

The present invention is directed to nicotinamide derivatives, and their use in treating gastrointestinal disorders.

2.	(WO 2009/042092) 2-ARYL OR HETEROARYL INDOLE DERIVATIVES	02.04.2009	A01N 43/42	PCT/ US2008/010

The present invention provides 2-aryl or heteroaryl indole derivatives which are ASIC channel modulators, pharmaceutical compositions compounds, and methods of using them as therapeutic agents

3.	(WO 2009/039461) N-SUBSTITUTED PIPERIDINE DERIVATIVES AS SEROTONIN RECEPTOR AGENTS	26.03.2009	C07D 211/58	PCT/ US2008/077

Disclosed herein are isolated forms of the compounds of Formula (I), (II), (III), (IV) and (V), or a pharmaceutically acceptable salt, prodr polymorph, or ester thereof. Also disclosed are methods of inhibiting an activity of a serotonin receptor, methods inhibiting an activation methods of alleviating or treating various disease conditions and side effects.

4.	(WO 2009/034380) PIPERIDINE DERIVATIVES AS AGONISTS OF MUSCARINIC RECEPTORS	19.03.2009	C07D 211/74	PCT/ GB2008/050

Compounds of Formula (I), or pharmaceutically acceptable salts thereof; wherein R<sp>2</sp>, R<sp>3</sp>, X, m and n are as define well as salts and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the ma

5.	(WO 2009/027697) NON-AQUEOUS PHARMACEUTICAL COMPOSITIONS	05.03.2009	A61K 9/00	PCT/ GB2008/002

The present invention provides a composition for intranasal delivery of a drug comprising: (i) the drug; and (ii) a non-aqueous vehicle co glycol and at least one additional solvent selected from N-methylpyrrolidone, propylene carbonate, dimethyl sulfoxide and at least one p ester; (b) from about 40 to 100 % by volume of N- methylpyrrolidone; or (c) from about 40 to 100% by volume of dimethyl sulfoxide (DM

6.	(WO 2009/024823) OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS	26.02.2009	C07D 211/40	PCT/



activities regarding patents and the PCT

GB2008/050

Disclosed herein is at least one cyclopropyl amide derivative of formula (I), at least one pharmaceutical composition comprising at least derivative disclosed herein, and at least one method of using at least one cyclopropyl amide derivative disclosed herein for treating at le receptor associated condition therewith.

7. (WO 2009/020642) PYRIDINE CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS 12.02.2009 A01N 37/16 PCT/US2008/009

The present invention is directed to pyridyl carboxamide compounds which are antagonists of orexin receptors, and which are useful in of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmac comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in whi involved.

8. (WO 2009/020569) TREATMENT OF PSYCHOSIS WITH A 5HT2A ANTAGONIST AND A METABOTROPIC GLUTAMATE RECEPTOR AGONIST OR POTENTIATOR 12.02.2009 C12N 5/06 PCT/US2008/009

The present invention is directed to the use of a 5-HT2A antagonist and an mGluR2/3 agonist, an mGluR2 agonist or an mGluR2 poten psychosis, including schizophrenia or bipolar disorder.

9. (WO 2009/018824) USE OF A COMPOSITION COMPRISING AT LEAST ONE BETA-BLOCKER FOR THE TREATMENT OF SLEEP DISORDERS 12.02.2009 A61K 31/165 PCT/DK2008/000

A composition comprising specific beta-blockers such as bisoprolol and nebivolol for the treatment of insomnia and/or another sleep dis should be given in such an amount that it causes a less than 40 % decrease in the amount of aMT6s in complete nocturnal urin. The co combination treatment comprising a specific beta-blocker in combination with another known drug e.g., **melatonin** with similar effect for

10. (WO 2009/017716) PULSATILE GASTRIC RETENTIVE DOSAGE FORMS 05.02.2009 A61K 9/00 PCT/US2008/009

Dosage forms for delayed and pulsed release of therapeutic agents into the stomach are described. The dosage forms are gastric reten achieve release of the therapeutic agent into the stomach and upper gastrointestinal tract subsequent to administration of the dosage fo particular use in administration of acid-labile active agents such as proton pump inhibitors, and in treating gastric acid secretion such as disease (GERD) and nocturnal acid breakthrough (NAB).

11. (WO 2009/017452) NEW CRYSTALLINE FORMS OF 2 -HYDROXY- 3- [5- (MORPHOLIN- 4- YLMETHYL) PYRIDIN-2-YL] IH- INDOLE- 5 -CARBONITRILE CITRATE 05.02.2009 C07D 413/14 PCT/SE2008/050

The present invention relates to new crystalline forms of 2-hydroxy-3-[5-(morpholin-4- ylmethyl)pyridin-2-yl]1H-indole-5-carbonitri Form E, respectively, a process for their preparations, pharmaceutical formulations containing said compounds and to the use of said a and particularly to GSK3 related conditions and disorders.

12. (WO 2009/011775) AMIDOETHYL ALKYLAMINO OREXIN RECEPTOR ANTAGONISTS 22.01.2009 A01N 43/64 PCT/US2008/008

The present invention is directed to amidoethylamine compounds which are antagonists of orexin receptors, and which are useful in the neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceu comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in whi involved.

13. (WO 2009/009015) QUINAZOLINONE T-TYPE CALCIUM CHANNEL ANTAGONISTS 15.01.2009 A01N 43/54 PCT/US2008/008

The present invention is directed to quinazolinone compounds which are antagonists of T-type calcium channels, and which are useful i prevention of disorders and diseases in which T-type calcium channels are involved. The invention is also directed to pharmaceutical co these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which T-type ca

involved.

14. (WO 2009/006403) NON-PEPTIDE MACROCYCLIC HISTONE DEACETYLASE (HDAC) INHIBITORS AND METHODS OF MAKING AND USING THEREOF — 08.01.2009 — A61K 31/7056 — PCT/US2008/068

Compounds of Formula (I) or (II), and methods of making and using thereof, are described herein, wherein M represents a macrolide su group, optionally containing one or more heteroatoms, wherein the carbon atoms and/or heteroatoms are in a linear and/or cyclic arrang group, A is a linking group connected to D, B is an alkyl, wherein M represents a macrolide subunit, R<sb>1</sb>, R<sb>2</sb> and R independently are selected from hydrogen, a C <sb>1-6</sb> alkyl group, a C<sb>2-6</sb> alkenyl group, a C<sb>2-6</sb> alkynyl gr

15. (WO 2008/157740) FAAH INHIBITORS — 24.12.2008 — C07D 209/30 — PCT/US2008/067

Indole derivatives that are useful for treating pain, inflammation and other conditions are described. Certain of the compounds are benz benzoyl derivatives. The compounds are substituted at least at the 3 position of the indole.

16. (WO 2008/155573) CINNOLINE COMPOUNDS FOR USE IN THE TREATMENT OF SCHIZOPHRENIA — 24.12.2008 — A61K 31/502 — PCT/GB2008/050

This invention relates to the use of compounds having the structural formula (I) below, and their pharmaceutically acceptable salts, tauto hydrolysable precursors, compositions in treating schizophrenia.

17. (WO 2008/155572) FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS — 24.12.2008 — C07D 471/14 — PCT/GB2008/050

This invention relates to novel compounds having the structural formula (I) below, and their pharmaceutically acceptable salts, tautomer precursors, compositions and methods of use thereof, wherein R<sp>1</sp>, R<sp>2</sp>, R<sp>3</sp>, R<sp>4</sp>, R<sp>5</sp> defined in the specification. These novel compounds provide a treatment or prophylaxis of anxiety disorders, schizophrenia, cognitive d disorders

18. (WO 2008/150364) CYCLOPROPYL PYRROLIDINE OREXIN RECEPTOR ANTAGONISTS — 11.12.2008 — A01N 43/62 — PCT/US2008/006

The present invention is directed to cyclopropyl proline bis-amide compounds which are antagonists of orexin receptors, and which are prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such d receptors are involved.

19. (WO 2008/148798) CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS FOR PROLONGED EFFECT — 11.12.2008 — A61K 9/20 — PCT/EP2008/056

Layered pharmaceutical composition suitable for oral use in the treatment of diseases where absorption takes place over a large part of The composition comprising A) a solid inner layer comprising i) an active substance, and ii) one or more disintegrants/exploding agents agents or a mixture thereof, the solid inner layer being sandwiched between two outer layers B1) and B2), each outer layer comprising soluble and/or crystalline polymer or a mixture of substantially water soluble and/or crystalline polymers, the polymer being a polyglycol homopolymer having a MW of at least about 100,000 daltons, and b) a copolymer having a MW of at l...

20. (WO 2008/147518) PYRIDYL PIPERIDINE OREXIN RECEPTOR ANTAGONISTS — 04.12.2008 — C07D 401/12 — PCT/US2008/006

The present invention is directed to pyridyl piperidine compounds of formula (I) which are antagonists of orexin receptors, and which ar prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such d receptors are involved.

21. (WO 2008/147314) SPIROCYCLOPROPYL PIPERIDINE DERIVATIVES 04.12.2008 C07D 405/04 PCT/SE2008/050

Disclosed herein is at least one piperidine derivative, at least one pharmaceutical composition comprising at least one piperidine derivat treating at least one histamine H3 receptor associated condition therewith

22. (WO 2008/143856) OXO BRIDGED DIAZEPAN OREXIN RECEPTOR ANTAGONISTS 27.11.2008 A01N 43/62 PCT/US2008/006

The present invention is directed to oxo bridged diazepan compounds which are antagonists of orexin receptors, and which are useful i of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmac comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in whi involved.

23. (WO 2008/137923) DROXIDOPA AND PHARMACEUTICAL COMPOSITION THEREOF FOR THE TREATMENT OF MOOD DISORDERS, SLEEP DISORDERS, OR ATTENTION DEFICIT DISORDERS 13.11.2008 A61K 31/138 PCT/US2008/062

The present invention provides pharmaceutical compositions comprising droxidopa alone, or in combination with one or more further ac treatment of conditions, such as mood disorders, sleep disorders, or attention deficit disorders. In certain embodiments, the composition the invention comprise droxidopa and a compound selected from the group consisting of DOPA decarboxylase inhibiting compounds, c inhibiting compounds, cholinesterase inhibiting compounds, monoamine oxidase inhibiting compounds, norepinephrine reuptake inhibiti serotonin reuptake inhibiting compounds, tricyclic antidepressant compounds, serotonin norepinephrine reuptake inhibi...

24. (WO 2008/136756) PYRROLOPYRIMIDIN-7-ONE DERIVATIVES AND THEIR USE AS PHARMACEUTICALS 13.11.2008 C07D 487/04 PCT/SE2008/050

Compounds of formula (I) or pharmaceutically acceptable salts thereof wherein R^1, R^2, R^3, R^4, and R^5 and are as defined in the specific pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pai

25. (WO 2008/130571) NUCLEAR RECEPTOR BINDING AGENTS 30.10.2008 C07C 327/00 PCT/US2008/004

The present invention relates to a novel class of selective estrogen receptor modulators (SERMs). The SERM compounds are applicabl and/or treatment of a variety of diseases and conditions including prevention and treatment of cancers such as prostate and breast can related diseases, hot flashes or vasomotor symptoms, neurological disorders, cardiovascular disease and obesity.

Next 25 records Start At

Search Summary

melatonin: 21695 occurrences in 2204 records.

zolpidem: 6704 occurrences in 1111 records.

(melatonin AND zolpidem). 251 records.

Search Time: 0.97 seconds.